| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
|
Lancet
|
2010
|
25.32
|
|
2
|
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
|
Lancet Oncol
|
2009
|
5.19
|
|
3
|
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
|
Lancet Oncol
|
2012
|
4.19
|
|
4
|
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
|
N Engl J Med
|
2015
|
3.09
|
|
5
|
Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites.
|
Cancer
|
2004
|
2.67
|
|
6
|
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
|
J Clin Oncol
|
2012
|
2.45
|
|
7
|
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus.
|
J Clin Oncol
|
2003
|
2.31
|
|
8
|
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
|
Clin Pharmacol Ther
|
2004
|
2.14
|
|
9
|
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
|
Pharmacogenet Genomics
|
2007
|
2.01
|
|
10
|
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
|
Oncol Rep
|
2006
|
1.91
|
|
11
|
Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions.
|
Gastrointest Endosc
|
2003
|
1.82
|
|
12
|
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.71
|
|
13
|
Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer.
|
Gastrointest Endosc
|
2005
|
1.71
|
|
14
|
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms.
|
Gastrointest Endosc
|
2002
|
1.70
|
|
15
|
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
|
J Clin Oncol
|
2010
|
1.69
|
|
16
|
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer.
|
Gastrointest Endosc
|
2002
|
1.55
|
|
17
|
Efficacy of preventive endoscopic balloon dilation for esophageal stricture after endoscopic resection.
|
J Clin Gastroenterol
|
2011
|
1.47
|
|
18
|
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
|
Cancer
|
2004
|
1.44
|
|
19
|
Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2015
|
1.39
|
|
20
|
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
|
J Vasc Interv Radiol
|
2012
|
1.38
|
|
21
|
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
|
J Clin Oncol
|
2006
|
1.34
|
|
22
|
Local recurrence of squamous-cell carcinoma of the esophagus after EMR.
|
Gastrointest Endosc
|
2005
|
1.34
|
|
23
|
Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region.
|
Carcinogenesis
|
2005
|
1.32
|
|
24
|
Gastric Cancer Working Group report.
|
Jpn J Clin Oncol
|
2010
|
1.31
|
|
25
|
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer.
|
Jpn J Clin Oncol
|
2005
|
1.29
|
|
26
|
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.
|
J Natl Cancer Inst
|
2013
|
1.28
|
|
27
|
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus.
|
Radiother Oncol
|
2008
|
1.28
|
|
28
|
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
|
Cancer
|
2011
|
1.27
|
|
29
|
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
|
Jpn J Clin Oncol
|
2004
|
1.26
|
|
30
|
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus.
|
Int J Radiat Oncol Biol Phys
|
2003
|
1.25
|
|
31
|
Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors.
|
Jpn J Clin Oncol
|
2009
|
1.21
|
|
32
|
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
|
Invest New Drugs
|
2010
|
1.21
|
|
33
|
mTOR as a therapeutic target in patients with gastric cancer.
|
Int J Cancer
|
2011
|
1.19
|
|
34
|
Magnifying narrow-band imaging versus magnifying white-light imaging for the differential diagnosis of gastric small depressive lesions: a prospective study.
|
Gastrointest Endosc
|
2010
|
1.19
|
|
35
|
EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer.
|
Gastrointest Endosc
|
2003
|
1.19
|
|
36
|
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
|
Gastric Cancer
|
2014
|
1.19
|
|
37
|
Long-term outcome of transoral organ-preserving pharyngeal endoscopic resection for superficial pharyngeal cancer.
|
Gastrointest Endosc
|
2011
|
1.18
|
|
38
|
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
|
Jpn J Clin Oncol
|
2013
|
1.15
|
|
39
|
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status.
|
Curr Colorectal Cancer Rep
|
2013
|
1.12
|
|
40
|
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.
|
Pharmacogenetics
|
2003
|
1.11
|
|
41
|
Endoscopic balloon dilatation for benign fibrotic strictures after curative nonsurgical treatment for esophageal cancer.
|
Surg Endosc
|
2012
|
1.08
|
|
42
|
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
|
Gastric Cancer
|
2011
|
1.08
|
|
43
|
A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer.
|
Am J Clin Oncol
|
2007
|
1.07
|
|
44
|
Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients.
|
Gastric Cancer
|
2012
|
1.04
|
|
45
|
Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer.
|
Gastric Cancer
|
2005
|
1.04
|
|
46
|
The role of chemotherapy in the current treatment of gastric cancer.
|
Gastric Cancer
|
2002
|
1.03
|
|
47
|
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
|
Invest New Drugs
|
2014
|
1.03
|
|
48
|
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five cases.
|
Cancer Chemother Pharmacol
|
2011
|
1.03
|
|
49
|
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
|
Hum Mutat
|
2004
|
1.03
|
|
50
|
Pulmonary tumor thrombotic microangiopathy associated with esophageal squamous cell carcinoma.
|
Intern Med
|
2011
|
1.02
|
|
51
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
52
|
Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I-II, diffuse large B-cell lymphoma of the stomach.
|
Cancer Sci
|
2005
|
1.01
|
|
53
|
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
|
BMC Cancer
|
2013
|
0.99
|
|
54
|
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
|
Clin Cancer Res
|
2010
|
0.99
|
|
55
|
EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.
|
Front Biosci (Landmark Ed)
|
2010
|
0.99
|
|
56
|
Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer.
|
Carcinogenesis
|
2002
|
0.97
|
|
57
|
Genetic variations and haplotypes of UGT1A4 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.97
|
|
58
|
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.
|
Drug Metab Pharmacokinet
|
2007
|
0.97
|
|
59
|
Usefulness of endoscopic radial incision and cutting method for refractory esophagogastric anastomotic stricture (with video).
|
Gastrointest Endosc
|
2012
|
0.96
|
|
60
|
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.96
|
|
61
|
Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study.
|
Int J Cancer
|
2012
|
0.96
|
|
62
|
Carcinoma coexisting with esophageal leiomyoma.
|
Gastrointest Endosc
|
2002
|
0.96
|
|
63
|
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
|
J Hum Genet
|
2007
|
0.96
|
|
64
|
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.
|
Jpn J Clin Oncol
|
2012
|
0.95
|
|
65
|
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
|
Clin Colorectal Cancer
|
2011
|
0.95
|
|
66
|
A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection.
|
World J Gastroenterol
|
2010
|
0.94
|
|
67
|
Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.
|
Int J Oncol
|
2006
|
0.94
|
|
68
|
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
|
Int J Clin Oncol
|
2008
|
0.94
|
|
69
|
Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research.
|
PLoS One
|
2011
|
0.92
|
|
70
|
Sequential methotrexate and 5-fluorouracil therapy for gastric cancer patients with bone metastasis.
|
Gastric Cancer
|
2000
|
0.92
|
|
71
|
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
|
Gastric Cancer
|
2012
|
0.92
|
|
72
|
Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
|
Drug Metab Dispos
|
2008
|
0.91
|
|
73
|
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
|
Jpn J Clin Oncol
|
2011
|
0.91
|
|
74
|
Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Sci
|
2014
|
0.90
|
|
75
|
Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
|
Gastric Cancer
|
2003
|
0.90
|
|
76
|
Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
|
Cancer Sci
|
2010
|
0.90
|
|
77
|
Epstein-Barr virus involvement is a predictive factor for the resistance to chemoradiotherapy of gastric diffuse large B-cell lymphoma.
|
Cancer Sci
|
2006
|
0.90
|
|
78
|
Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
|
Cancer
|
2008
|
0.89
|
|
79
|
Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
|
Jpn J Clin Oncol
|
2010
|
0.89
|
|
80
|
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
|
Gastric Cancer
|
2011
|
0.89
|
|
81
|
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.
|
Jpn J Clin Oncol
|
2004
|
0.89
|
|
82
|
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
|
Int J Clin Oncol
|
2012
|
0.88
|
|
83
|
Non-surgical approach to small cell carcinoma of the esophagus: does this rare disease have the same tumor behavior as SCLC?
|
Int J Clin Oncol
|
2011
|
0.88
|
|
84
|
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
|
Br J Clin Pharmacol
|
2010
|
0.87
|
|
85
|
Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.87
|
|
86
|
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
|
Drug Metab Pharmacokinet
|
2006
|
0.87
|
|
87
|
Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.
|
Jpn J Clin Oncol
|
2014
|
0.87
|
|
88
|
Treatment strategy for superficial pharyngeal squamous cell carcinoma synchronously combined with esophageal cancer.
|
Oncology
|
2012
|
0.87
|
|
89
|
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.
|
Drug Metab Pharmacokinet
|
2003
|
0.86
|
|
90
|
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
|
Jpn J Clin Oncol
|
2007
|
0.86
|
|
91
|
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
|
Invest New Drugs
|
2012
|
0.86
|
|
92
|
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
|
Anticancer Res
|
2012
|
0.86
|
|
93
|
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
|
J Pharmacol Exp Ther
|
2003
|
0.86
|
|
94
|
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer.
|
Gastric Cancer
|
2013
|
0.86
|
|
95
|
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
|
Int J Clin Oncol
|
2011
|
0.85
|
|
96
|
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2006
|
0.85
|
|
97
|
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study.
|
Gastric Cancer
|
2002
|
0.85
|
|
98
|
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
|
Gastric Cancer
|
2013
|
0.85
|
|
99
|
Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy.
|
Clin Cancer Res
|
2002
|
0.84
|
|
100
|
A novel gene-protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneity.
|
Gastric Cancer
|
2014
|
0.84
|
|
101
|
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
|
J Biosci Bioeng
|
2013
|
0.84
|
|
102
|
Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.
|
J Cancer Res Clin Oncol
|
2013
|
0.84
|
|
103
|
Genetic polymorphisms of UGT1A6 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.84
|
|
104
|
Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer.
|
Gastric Cancer
|
2000
|
0.84
|
|
105
|
Does daily alcohol and/or cigarette consumption cause low-grade dysplasia, a precursor of esophageal squamous cell carcinoma?
|
J Clin Gastroenterol
|
2010
|
0.83
|
|
106
|
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
|
Jpn J Clin Oncol
|
2009
|
0.83
|
|
107
|
Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
|
Oncol Rep
|
2004
|
0.83
|
|
108
|
Functional analysis of four naturally occurring variants of human constitutive androstane receptor.
|
Mol Genet Metab
|
2005
|
0.83
|
|
109
|
Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.
|
Jpn J Clin Oncol
|
2010
|
0.83
|
|
110
|
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
|
Int J Clin Oncol
|
2008
|
0.82
|
|
111
|
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2008
|
0.82
|
|
112
|
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
|
Oncologist
|
2014
|
0.82
|
|
113
|
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
|
Cancer Chemother Pharmacol
|
2015
|
0.81
|
|
114
|
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
|
Gastric Cancer
|
2013
|
0.81
|
|
115
|
Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
116
|
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
|
Int J Clin Oncol
|
2009
|
0.81
|
|
117
|
Implantation of self-expanding metallic stent for patients with malignant stricture after failure of definitive chemoradiotherapy for T3 or T4 esophageal squamous cell carcinomas.
|
Hepatogastroenterology
|
2002
|
0.81
|
|
118
|
A phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410).
|
Jpn J Clin Oncol
|
2002
|
0.81
|
|
119
|
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
120
|
Neoadjuvant chemotherapy with S-1 for scirrhous gastric cancer: a pilot study.
|
Gastric Cancer
|
2003
|
0.81
|
|
121
|
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
|
Drug Metab Dispos
|
2007
|
0.81
|
|
122
|
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.
|
Drug Metab Pharmacokinet
|
2009
|
0.81
|
|
123
|
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2007
|
0.81
|
|
124
|
Causal relationships between esophageal squamous cell carcinoma and nephrotic syndrome.
|
Intern Med
|
2009
|
0.81
|
|
125
|
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2007
|
0.80
|
|
126
|
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
|
Jpn J Clin Oncol
|
2010
|
0.80
|
|
127
|
Depressed-type (0-IIc) colorectal neoplasm in patients with family history of first-degree relatives with colorectal cancer: A cross-sectional study.
|
World J Gastroenterol
|
2006
|
0.80
|
|
128
|
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
|
Jpn J Clin Oncol
|
2007
|
0.80
|
|
129
|
Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
|
Drug Metab Dispos
|
2005
|
0.80
|
|
130
|
Phase I study of olaratumab in Japanese patients with advanced solid tumors.
|
Cancer Sci
|
2014
|
0.80
|
|
131
|
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
|
Jpn J Clin Oncol
|
2003
|
0.79
|
|
132
|
Induction chemotherapy with docetaxel, cisplatin and S-1 followed by proton beam therapy concurrent with cisplatin in patients with T4b nasal and sinonasal malignancies.
|
Jpn J Clin Oncol
|
2012
|
0.79
|
|
133
|
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
|
Jpn J Clin Oncol
|
2005
|
0.79
|
|
134
|
Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
|
Jpn J Clin Oncol
|
2012
|
0.79
|
|
135
|
Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials.
|
Gastric Cancer
|
2000
|
0.78
|
|
136
|
Five-year survivor with liver metastasis from gastric cancer successfully treated with systemic chemotherapy.
|
Gastric Cancer
|
2000
|
0.78
|
|
137
|
Three novel single nucleotide polymorphisms in UGT1A9.
|
Drug Metab Pharmacokinet
|
2003
|
0.78
|
|
138
|
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.78
|
|
139
|
Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population.
|
Drug Metab Dispos
|
2005
|
0.77
|
|
140
|
Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy.
|
J Gastroenterol
|
2007
|
0.77
|
|
141
|
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
|
Invest New Drugs
|
2013
|
0.77
|
|
142
|
Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population.
|
Drug Metab Pharmacokinet
|
2003
|
0.77
|
|
143
|
Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2013
|
0.77
|
|
144
|
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.
|
Immunogenetics
|
2012
|
0.77
|
|
145
|
Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population.
|
Drug Metab Pharmacokinet
|
2004
|
0.77
|
|
146
|
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.
|
Invest New Drugs
|
2015
|
0.76
|
|
147
|
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
|
Jpn J Clin Oncol
|
2007
|
0.76
|
|
148
|
Patients' perception of the usefulness of a question prompt sheet for advanced cancer patients when deciding the initial treatment: a randomized, controlled trial.
|
Psychooncology
|
2011
|
0.76
|
|
149
|
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
150
|
Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.76
|
|
151
|
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
|
Jpn J Clin Oncol
|
2008
|
0.76
|
|
152
|
Computer-assisted analysis of biopsy specimen microvessels predicts the outcome of esophageal cancers treated with chemoradiotherapy.
|
Clin Cancer Res
|
2006
|
0.76
|
|
153
|
Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).
|
Drug Metab Pharmacokinet
|
2003
|
0.75
|
|
154
|
Advanced esophageal cancer with esophago-bronchial fistula successfully treated by chemoradiation therapy with additional endoscopic resection: a case report.
|
Jpn J Clin Oncol
|
2002
|
0.75
|
|
155
|
TS gene tandem repeats in esophageal cancer patients receiving chemoradiotherapy.
|
Front Biosci (Landmark Ed)
|
2011
|
0.75
|
|
156
|
Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.
|
Drug Metab Pharmacokinet
|
2010
|
0.75
|
|
157
|
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
|
Cancer Med
|
2012
|
0.75
|
|
158
|
Three novel single nucleotide polymorphisms in UGT1A10.
|
Drug Metab Pharmacokinet
|
2002
|
0.75
|
|
159
|
Ramucirumab for gastric cancer.
|
Expert Rev Gastroenterol Hepatol
|
2014
|
0.75
|
|
160
|
Psychological states and coping strategies after bereavement among spouses of cancer patients: a quantitative study in Japan.
|
Support Care Cancer
|
2012
|
0.75
|
|
161
|
A pilot study of post-operative radiotherapy with concurrent chemotherapy for high-risk squamous cell carcinoma of the cervical esophagus.
|
Jpn J Clin Oncol
|
2011
|
0.75
|
|
162
|
[Current status and issues in early & exploratory oncology clinical trials in Japan].
|
Nihon Rinsho
|
2015
|
0.75
|
|
163
|
Epidermoid metaplasia of the esophagus: endoscopic feature and differential diagnosis.
|
Hepatogastroenterology
|
2011
|
0.75
|
|
164
|
Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials.
|
Oncology
|
2017
|
0.75
|
|
165
|
[Globalization of clinical trials].
|
Gan To Kagaku Ryoho
|
2003
|
0.75
|
|
166
|
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
|
Nihon Rinsho
|
2003
|
0.75
|
|
167
|
Current progress of cancer chemotherapy The Fifteenth International Symposium of the Hiroshima Cancer Seminar, October 2005.
|
Cancer Sci
|
2006
|
0.75
|
|
168
|
Successful endosocpic submucosal dissection for esophageal squamous cell carcinoma together with a lipoma.
|
Hepatogastroenterology
|
2011
|
0.75
|
|
169
|
Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
170
|
[Retrospective analysis of antiemetic effect in patients receiving cisplatin].
|
Gan To Kagaku Ryoho
|
2011
|
0.75
|
|
171
|
[Current topics on molecular targeting drugs for gastric cancer].
|
Gan To Kagaku Ryoho
|
2010
|
0.75
|
|
172
|
[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
|
Gan To Kagaku Ryoho
|
2009
|
0.75
|
|
173
|
[Chemotherapy with molecular targeting agents for colorectal cancer].
|
Nihon Rinsho
|
2012
|
0.75
|
|
174
|
Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.
|
Drug Metab Dispos
|
2003
|
0.75
|
|
175
|
Impaired mental health among the bereaved spouses of cancer patients.
|
Psychooncology
|
2012
|
0.75
|
|
176
|
Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.75
|
|
177
|
[Chemoradiotherapy].
|
Nihon Rinsho
|
2011
|
0.75
|